Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: A randomized controlled trial.

Hydroxychloroquine for the treatment of severe respiratory infection by COVID-19: A randomized controlled trial.

<h4>Introduction</h4>The novel coronavirus pandemic (COVID-19) represents a major public health problem and it is key to find a treatment that reduces mortality. Our objective was to estimate whether treatment with 400 mg/day of Hydroxychloroquine for 10 days reduces in-hospital mortalit...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Carmen Hernandez-Cardenas, Ireri Thirion-Romero, Sebastián Rodríguez-Llamazares, Norma E Rivera-Martinez, Patricia Meza-Meneses, Arantxa Remigio-Luna, Rogelio Perez-Padilla, Research Group on hydroxychloroquine for COVID-19
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/865a4ab2b6794dd8b110faeb5370270f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares